Clonal Hematopoiesis Linked to Increased Risk of Venous Thromboembolism

Strategic Insights -

Research from the University of Alabama Birmingham has revealed a significant association between clonal hematopoiesis and the risk of venous thromboembolism (VTE) in patients who have undergone autologous peripheral blood stem cell transplantation for lymphoma. According to the study, patients with clonal hematopoiesis were found to have a higher risk of VTE compared to those without the condition.

Key Takeaways:

  • The study included 557 patients with lymphoma who had survived 2 or more years after receiving autologous peripheral blood stem cell transplantation between 1999 and 2014.
  • Clonal hematopoiesis was detected in 36.1% of patients, and the 8-year cumulative incidence of VTE was 8.2% among those with clonal hematopoiesis, compared to 3.6% among patients without clonal hematopoiesis.
  • The presence of PPM1D mutation (hazard ratio = 4.12, 95% CI = 1.55 to 10.92) or TP53 mutation (hazard ratio = 5.31, 95% CI = 1.54 to 18.35) was associated with VTE risk in adjusted analysis.
  • The study was funded by the National Institutes of Health (NIH) - USA.
  • Additional findings suggested that patients with clonal hematopoiesis were at increased risk of VTE, regardless of the presence of PPM1D or TP53 mutations.

Statistics:

  • 36.1% of patients had clonal hematopoiesis.
  • 8.2% of patients with clonal hematopoiesis experienced VTE within 8 years.
  • 3.6% of patients without clonal hematopoiesis experienced VTE within 8 years.
  • PPM1D mutation was associated with a 4.12-fold increased risk of VTE (95% CI = 1.55 to 10.92).
  • TP53 mutation was associated with a 5.31-fold increased risk of VTE (95% CI = 1.54 to 18.35).

Sources:

  • JNCI: Journal of the National Cancer Institute, 2025.
  • NewsRx. New Venous Thromboembolism Findings Has Been Reported by Investigators at University of Alabama Birmingham (Clonal Hematopoiesis and Subsequent Venous Thromboembolism Among Survivors of Autologous Transplantation for Lymphoma). Hematology Week. October 20, 2025; p 1212.